Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by IFP Advisors Inc

IFP Advisors Inc raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,230 shares of the biopharmaceutical company’s stock after buying an additional 206 shares during the quarter. IFP Advisors Inc’s holdings in Regeneron Pharmaceuticals were worth $646,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in REGN. E Fund Management Hong Kong Co. Ltd. grew its holdings in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 31 shares in the last quarter. Activest Wealth Management grew its holdings in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. Finally, Colonial Trust Advisors purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $32,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $557.73 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,024.36. The firm has a market capitalization of $59.11 billion, a PE ratio of 14.06, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. The stock’s 50-day simple moving average is $573.67 and its 200-day simple moving average is $563.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the company earned $11.56 EPS. The business’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Analysts Set New Price Targets

Several analysts have issued reports on REGN shares. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Jefferies Financial Group increased their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research note on Monday, August 4th. Finally, Citigroup increased their target price on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $817.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.